SCHOELLER ALLIBERT CONTRIBUTES IN THE GLOBAL BATTLE AGAINST COVID-19 WITH CG Chemikalien GmbH & Co. KG
When scientists began seeking a vaccine in early 2020, they were very careful in communicating a possible delivery date. The development of a vaccine is something that cannot be rushed and the fastest any vaccine had previously been developed from sample to approved vaccine, was 4 years.
The future of vaccine science has been changed thanks to the COVID-19 experience. Early December 2020 the first pharmaceutical companies, requested approval for the first fully tested immunization for emergency use.
The official first emergency use authorization (EUA) for a COVID-19 vaccine was given on December 11, 2020. This authorization allows the distribution in the U.S. The EMA (European Medicines Agency) followed by recommending it for authorization in the EU on Dember 21; 2020. The next challenge lies now to produce it in massive quantities to supply it on a global level.
At Schoeller Allibert we understand that this can be very challenging and we have undertaken action to make sure that CG Chemikalien GmbH & Co. KG have the best quality intermediate bulk containers (ComboLife® IBC 65) to securely transport their liquid raw materials to the pharmaceutical companies so production of the COVID-19 vaccine will not be delayed due to lack of raw materials.
When transporting liquid raw materials of such a high value it is important to make sure the option of tamper evidence and strapping is available to ensure safety. Our foldable intermediate bulk containers (IBC) are safe, hygienic, and efficient for pharmaceutical industries and make sure that after use the IBC can be returned and reused.
Want to track the IBC in the logistics flow? No problem, while multiple identification and tracking options are possible. The barcode labels and RFID & IOT pockets enable efficient fleet management.
ComboLife® top benefits
Link to ComboLife® 65 on the website
Combo Excelsior Hybrid® benefits
Link to Combo Excelsior Hybrid®